Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIE | Q9UNP9 | 1/20 | 0.95 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.31 |
| ▸ | IDE | P14735 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23512388 | 0.97 | PPIE (1.00) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL25146703 | 0.96 | PPIE (0.96) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL23512300 | 0.96 | PPIE (0.96) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL25146723 | 0.96 | PPIE (0.95) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL25146936 | 0.96 | PPIE (0.95) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL25146434 | 0.95 | PPIE (0.94) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL23512529 | 0.95 | PPIE (0.94) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL26955733 | 0.95 | PPIE (0.94) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL23512639 | 0.95 | PPIE (0.94) | PPIESLC40A1GHSRANPEPLNPEP | |
| SCHEMBL23512638 | 0.95 | PPIE (0.94) | PPIESLC40A1GHSRANPEPLNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2021119249-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | PPID, PPIF, PPIL1 | PPIE 7/4885SLC40A1 1351/4885GHSR 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.